下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications.
Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们确定了两种内膜肉瘤分子亚型。与 CNV-H 相比,MSI-H-like 富集于与肿瘤免疫应答和 TIL 相关的通路。需要进一步的努力和临床试验来更好地定义这些分子亚型,从而为个性化治疗方法开辟新途径并改善患者预后。
内膜肉瘤是一种罕见且侵袭性强的软组织肉瘤,治疗选择有限。我们探索了内膜肉瘤的基因组图谱,以揭示治疗意义。
我们分析了就诊于首尔国立大学医院(SNUH)的内膜肉瘤患者的肿瘤组织,采用全外显子、全转录组和临床下一代测序(NGS),并与来自两个公共队列的内膜肉瘤NGS数据进行整合。我们根据分子亚型检查了表达特征和TIL(肿瘤浸润淋巴细胞)(TILs)。
我们的研究共纳入42份样本。33例显示拷贝数变异(CNV)富集且频繁出现CDK4/MDM2扩增的患者被归类为CNV-high(CNV-H)亚型。5例显示以MLH1突变或纯合缺失为主的患者被归类为微卫星高度不稳定样(MSI-H-like)亚型。在CNV-H亚型中上调的标志性通路包括Wnt β-catenin和Hedgehog信号通路。在MSI-H-like亚型中,干扰素-γ反应、通过核因子-κB的肿瘤坏死因子-α信号通路、干扰素-α反应、炎症反应以及白细胞介素-6-Jak-Stat3信号通路上调。CNV-H亚型样本主要显示免疫荒漠表型,而MSI-H-like亚型样本主要显示免疫炎症表型。2例MSI-H-like亚型患者接受了pembrolizumab治疗并出现肿瘤缩小。
Intimal sarcoma is a rare and aggressive soft-tissue sarcoma with limited treatment options. We explored genomic profiles of intimal sarcoma to uncover therapeutic implications.
We analyzed tumor tissues from patients with intimal sarcoma who visited the Seoul National University Hospital (SNUH) using whole-exome, whole-transcriptome, and clinical next-generation sequencing (NGS), integrated with intimal sarcoma NGS data from two public cohorts. We examined expression characteristics and tumor-infiltrating lymphocytes (TILs) according to molecular subtypes.
Our study included 42 samples in total. Thirty-three patients showing copy number variation (CNV) enrichment with frequent CDK4/MDM2 amplifications were classified as the CNV-high (CNV-H) subtype. Five patients showing predominant MLH1 mutations or homozygous deletions were classified as the microsatellite instability-high-like (MSI-H-like) subtype. Hallmark pathways up-regulated in the CNV-H subtype included Wnt β-catenin and Hedgehog signaling. In the MSI-H-like subtype, interferon-γ response, tumor necrosis factor-α signaling via nuclear factor-κB, interferon-α response, inflammatory response, and interleukin-6-Jak-Stat3 signaling were up-regulated. CNV-H subtype samples predominantly showed an immune-desert phenotype, whereas MSI-H-like subtype samples predominantly showed an immune-inflamed phenotype. Two MSI-H-like subtype patients received pembrolizumab and experienced tumor shrinkage.
We identified two intimal sarcoma molecular subtypes. Compared with CNV-H, MSI-H-like is enriched in pathways associated with tumor immune responses and TILs. Further efforts and clinical trials to better define these molecular subtypes are warranted to open new avenues for personalized treatment approaches and improve patient outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。